Izuel Rami Mónica, Gómez Barrera Manuel, Villar Fernández Isabel, Rabanaque Hernández María José, Cuenca Espiérrez Jorge, García-Erce José Antonio
Servicio de Farmacia Hospitalaria, Hospital Universitario Miguel Servet, P. Isabel La Católica 1-3, 50009 Zaragoza, Spain.
Med Clin (Barc). 2007 Jan 13;128(1):7-11. doi: 10.1157/13096938.
To assess the cost-effectiveness and the budget impact of a Blood Saving Program (BSP) in patients older than 65 undergoing perthrocanteric hip fracture surgery.
Two groups of patients with perthrocanteric fracture were included. Group 1: patients not receiving treatment for perisurgical anaemia or treated with oral iron; Group 2: patients included in a BSP (treatment with endovenous iron sucrose and alfa epoetin, plus restrictive transfusional criteria). Effectiveness issues were: transfusion rate and number of red blood cell units transfused, length of postoperative stay and infection rate. Treatment cost was calculated using drug and transfused red blood cell unit prizes in 2003. We calculated potential patient population according to 2003 data.
144 patients were included, 43 of which were in the BSP. Both groups were comparable in gender, age, preoperative length of stay, ASA and haemoglobin level at admission. Patients included in the BSP were less transfused and had less infections but postoperative stay was similar in both groups. The budget impact was 239,148 euros 95% [confidence interval (CI) 202,312-311,980] at group 1 and 311,980 euros [95% CI 275,288-348,672] at the BSP group. Including the whole potential population in the BSP (during one year 400 patients) would mean a cost increase of 72,832 euros, avoiding transfusion in 92 patients, infection in 70 patients, and saving 328 red blood cell units.
The cost increase due to endovenous iron sucrose and alfa-epoetin can be considered affordable for the hospital budget. BSP provides lower transfusion and infection rates and saves red blood cell units, compared to the standard procedure. Differences in postoperative stay should be analyzed in further larger and prospective studies including more patients.
评估一项血液节约计划(BSP)对65岁以上接受股骨转子周围骨折手术患者的成本效益及预算影响。
纳入两组股骨转子周围骨折患者。第1组:未接受围手术期贫血治疗或仅接受口服铁剂治疗的患者;第2组:纳入BSP的患者(接受静脉注射蔗糖铁和促红细胞生成素α治疗,外加限制性输血标准)。有效性指标包括:输血率、输注红细胞单位数量、术后住院时间及感染率。使用2003年的药品及输注红细胞单位价格计算治疗成本。根据2003年数据计算潜在患者人群数量。
共纳入144例患者,其中43例在BSP组。两组在性别、年龄、术前住院时间、美国麻醉医师协会(ASA)分级及入院时血红蛋白水平方面具有可比性。BSP组患者输血较少且感染较少,但两组术后住院时间相似。第1组的预算影响为239,148欧元[95%置信区间(CI)202,312 - 311,980],BSP组为311,980欧元[95%CI 275,288 - 348,672]。将整个潜在人群纳入BSP(一年内400例患者)将意味着成本增加72,832欧元,可避免92例患者输血、70例患者感染,并节省328个红细胞单位。
对于医院预算而言,静脉注射蔗糖铁和促红细胞生成素α导致的成本增加可认为是可承受的。与标准治疗程序相比,BSP可降低输血率和感染率,并节省红细胞单位数量。术后住院时间的差异应在纳入更多患者的进一步大规模前瞻性研究中进行分析。